Neurophyxia

Neurophyxia's main objective is to develop 2-iminobiotin (or 2-IB) as a novel injectable pharmaceutical product

Neurophyxia operates in biotechnology based in European Union (EU), Europe, Middle East, and Africa (EMEA), founded in 2008.

The company sits in the biotechnology segment, where it competes on its core product or service.

The company is recorded as being based in European Union (EU), Europe, Middle East, and Africa (EMEA).

Directory data places it at the Private company stage.

Sector	Biotechnology
Headquarters	European Union (EU), Europe, Middle East, and Africa (EMEA)
Founded	2008
Stage	Private company

Website: www.neurophyxia.com

Emails and contact routes are reserved for registered members.
Create a free account

Browse related